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Abstract
A protein isolated from the bark of Crataeva tapia (CrataBL) is both a Kunitz-type plant protease inhibitor and a lectin. We
have determined the amino acid sequence and three-dimensional structure of CrataBL, as well as characterized its selected
biochemical and biological properties. We found two different isoforms of CrataBL isolated from the original source,
differing in positions 31 (Pro/Leu); 92 (Ser/Leu); 93 (Ile/Thr); 95 (Arg/Gly) and 97 (Leu/Ser). CrataBL showed relatively weak
inhibitory activity against trypsin (Kiapp = 43 mM) and was more potent against Factor Xa (Kiapp = 8.6 mM), but was not active
against a number of other proteases. We have confirmed that CrataBL contains two glycosylation sites and forms a dimer at
high concentration. The high-resolution crystal structures of two different crystal forms of isoform II verified the b-trefoil fold
of CrataBL and have shown the presence of dimers consisting of two almost identical molecules making extensive contacts
(,645 A˚2). The structure differs from those of the most closely related proteins by the lack of the N-terminal b-hairpin. In
experiments aimed at investigating the biological properties of CrataBL, we have shown that addition of 40 mM of the
protein for 48 h caused maximum growth inhibition in MTT assay (47% of DU145 cells and 43% of PC3 cells). The apoptosis
of DU145 and PC3 cell lines was confirmed by flow cytometry using Annexin V/FITC and propidium iodide staining.
Treatment with CrataBL resulted in the release of mitochondrial cytochrome c and in the activation of caspase-3 in DU145
and PC3 cells.
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Introduction
A large number of proteins are characterized by their b-trefoil
fold [1]. Members of this superfamily share structural features but
not necessarily other properties and their biological role may be
widely different [2]. Prominent among them are plant protease
inhibitors of the Kunitz type, called Kunitz-P or Kunitz-STI
inhibitors [2,3]. These proteins primarily inhibit serine proteases,
although some also inhibit cysteine and aspartic proteases [4].
Kunitz-P inhibitors are characterized by molecular mass of about
20,000 Da (for the whole protein or a domain), low content of
cysteine residues, and one or two reactive sites that are the basis of
their inhibitory activity. However, some structurally related b-
trefoil proteins are not protease inhibitors at all, but exhibit varied
other properties, for example chlorophyll binding [5], taste
modification (miraculin) [6], binding to cytokine receptors (IL-
1b) [7], ribosome poisoning (ricin) [8] or carbohydrate binding,
exemplified by the Clitocybe nebularis lectin, CNL [9].
Plant lectins are proteins that possess at least one non-catalytic
domain that binds reversibly and specifically mono- or oligosac-
charides [10,11]. Owing to these properties, such proteins are
being utilized in characterization of glycoconjugates and in cell-
surface or cell-cell architecture studies [12,13]. A few protease
inhibitors also show lectin activity, an example provided by the
inhibitor isolated from the epidermis of the eel, named Eel-CPI-1
[14]. Troncoso et al. [15] isolated an inhibitor with lectin
properties from Peltophorum dubium seeds which decreases the
viability of the Nb2 rat lymphoma cells.
Crataeva tapia (also known as Crateva tapia) belongs to the
Capparaceae family that is found in northeastern Brazil. A protein
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from the Crataeva tapia bark has been purified using reversed
micelles in isooctane [16] and through chromatographic processes
[17]. Named CrataBL (Crataeva tapia Bark Lectin), this protein was
shown to possess some specificity for binding glucose and galactose
[17]. A number of its biological properties have been character-
ized, including delay in clot formation by impairing the intrinsic
pathway of coagulation cascade [18]. In addition, CrataBL was
shown to exhibit anti-inflammatory, analgesic [19], insecticidal
[17], and anti-tumor [19] activities.
Prostate cancer is the most common cancer in men [20], with
DU145 and PC3 being the most extensively studied prostate
cancer cell lines that serve as in vitro models for cancer treatment
studies [21,22,23]. Prostate cancer is associated with a high level of
expression of proteases [24] and glycoproteins [25], making
CrataBL a potentially useful tool for studies involving prostate
cancer cell lines, due to its combination of properties that include
both protease inhibition and carbohydrate binding.
In this work, we determined the amino acid sequence and the
three-dimensional structure of CrataBL and also investigated a
range of biochemical activities, comparing them to the properties
of other members of this superfamily. Subsequently, we charac-
terized the effect of CrataBL on growth and stability of human
prostate cancer cell lines.
Materials and Methods
Isolation of CrataBL
Isolation of the protein was performed according to the
procedure of Arau´jo et al. [17]. Briefly, 10% (w/v) extracts from
Crataeva tapia bark were fractionated with 30–60% ammonium
sulfate. The fraction containing the protein was dialyzed against
10 mM phosphate citrate buffer pH 5.5 and applied to a column
of CM-cellulose equilibrated with the same buffer. Adsorbed
protein was eluted with an equilibration buffer containing 0.5 M
NaCl and contents of the single peak were submitted to size
exclusion chromatography on Superdex 75 column, equilibrated
in 0.15 M NaCl using an DKTA Purifier (GE Healthcare,
Uppsala, Sweden). This was followed by high performance liquid
chromatography (HPLC) on a C18 column, to confirm the
homogeneity of the sample. The elutions were monitored at
280 nm.
Protein concentration and carbohydrate assays
Protein determination was carried out as described by Lowry et
al. [26] using bovine serum albumin (BSA) as the standard. The
sugar content of CrataBL was determined by phenol-sulfuric acid
method of Masuko et al. [27], with mannose at concentrations of
2, 4, 6, 8, and 10 mg as a standard.
MALDI-TOF/MS analysis
The molecular mass of CrataBL was analyzed by MALDI-
TOF/MS. 1 mL CrataBL (2 mg/mL) was added to 1 mL of a-
cyano-4-hydroxycinnamic acid (10 mg/mL) matrix solution,
spotted onto a stainless steel MALDI target plate and dried at
room temperature before analysis. Mass spectra were obtained
with a Bruker Daltonics Microflex LT instrument (Billerica, USA)
operating in linear, positive ion mode, previously calibrated with
insulin, ubiquitin, cytochrome C, and myoglobin. For the analysis
of the protein, mass spectra were acquired using the following
instrument parameters: pulsed ion extraction delay of 30 ns, ion
source voltage one, 20 kV, ion source voltage two, 18.65 kV, and
ion source lens voltage 7.1 kV. For each sample, mass spectra were
acquired by accumulating 50 laser shots at 50% laser power in the
m/z range of 8000–25000 Da.
Primary structure of CrataBL
The sequencing of the native protein was performed by Edman
degradation [28]. The sample was reduced, alkylated, and then
submitted to digestion with trypsin, chymotrypsin, Asp-N, and
Lys-C endopeptidases (sequencing grade, Roche, Germany).
Fragments resulting from the treatment with endopeptidases were
purified on a 16150 mm Jupiter Proteo 90A column (Phenom-
enex, Aschaffenburg, Germany) at a flow rate of 0.1 mL/min,
using an acetonitrile gradient (0–60%) with 0.1% (v/v) trifluor-
oacetic acid for 40 min. Sequencing was performed on an
automatic gas-phase sequencer (492cLC; Applied Biosystems,
Foster City, USA). The glycosylated peptides were analyzed by
mass spectrometry to determine the molecular mass of the
carbohydrate moieties. Sequence similarities were assessed with
the program BLAST against the NCBI protein database [29]. The
sequences were aligned using the program MULTALIN [30].
Enzyme inhibition assays
The inhibitory activity of CrataBL against proteases was
measured using specific chromogenic or fluorogenic substrates in
96-well microtiter plates at 37uC. The enzymes (human Factor
Xa, bovine trypsin, bovine chymotrypsin, human plasma kallikrein
(HuPK), porcine pancreatic kallikrein (PoPK), human neutrophil
elastase (HNE), human plasmin, and papain) were pre-incubated
with either CrataBL or with solvent for 10 min. The reactions
were initiated by the addition of the substrates, and the color or
fluorescence were monitored continuously at 405 nm using a
spectrophotometer (Packard, SpectraCount), or at 380/460 nm
using a Hitachi F-2000 spectrofluorimeter (Tokyo, Japan),
respectively, for 30 min, and stopped with the addition of 50 mL
of 30% (v/v) acetic acid. Enzymatic activities were analyzed in the
following buffers (final concentrations): human factor Xa (21 nM
in 0.02 M Tris-HCl, pH 7.4 containing 0.14 M NaCl, 5.0 mM
CaCl2 and 0.1% bovine serum albumin; 0.57 mM Boc-Ile-Glu-
Gly-Arg-AMC); bovine trypsin (40 nM in 0.1 M Tris-HCl,
pH 8.0 containing 0.02% (v/v) CaCl2; 0.8 mM Bz-Arg-pNan);
bovine chymotrypsin (88 nM in 0.05 M Tris-HCl, pH 8.0;
0.8 mM Suc-Phe-pNan); HuPK (14.7 nM in 0.1 M Tris-HCl,
pH 8.0 containing 0.5 M NaCl; 0.4 mM H-D-Pro-Phe-Arg-
pNan); PoPK (2.6 nM in 0.1 M Tris-HCl, pH 9.0; 0.16 mM
HD-Val-Leu-Arg-pNan); HNE (1.3 nM in 0.05 M Tris-HCl,
pH 7.0 containing 0.5 M NaCl; 0.88 mM MeO-Suc-Ala-Ala-
Pro-Val-pNan); human plasmin (3.5 nM in 0.1 M Tris-HCl,
pH 7.4 containing 0.2 M NaCl; 0.9 mM H-D-Val-Leu-Lys-pNan)
and papain (87 nM in 0.1 M Na2HPO4, pH 6.3 containing 0.4 M
NaCl, 0.01 M EDTA; 0.4 mM Z-Phe-Arg-pNan). The apparent
Kiapp values were determined by fitting the experimental points to
the equation for slow-tight binding [31] with the help of the Grafit
program, version 4.0 (Erithacus Software, Staines, UK) [32].
Reactive site determination by affinity chromatography
on trypsin-Sepharose
A sample containing 1.8 mg of protein in 0.1 M Tris-HCl
buffer pH 8.0 was applied to a 1.0 mL trypsin-Sepharose column
equilibrated with the same buffer. The inhibitor was eluted by
0.5 M KCl/HCl, pH 2.0 and kept in this pH until the N-terminal
determination step.
Protein crystallization
A highly purified protein sample pooled from a Superdex 75
column was dialyzed into a buffer consisting of 20 mM Tris
pH 8.0, 100 mM NaCl, and 3% glycerol, and then was
concentrated to 8.5 mg/mL using Centrifugal Filter Units
Crataeva tapia Lectin Characterization
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(Millipore, Billerica, MA). Initial crystallization trials were
performed using a Phoenix robot (Art Robbins Instruments,
Mountain View, CA). A number of hits were obtained from
several different crystallization screens [JCSG (Qiagen, Valencia,
CA), Crystal Screen HT, Index (Hampton Research, Aliso Viejo,
CA), and Wizard1-2 (Emerald Biosystems, Bedford, MA)].
Diffraction quality crystals were obtained from screens JCSG-
CORE-II D12 (0.2 M Li2SO4, 30% PEG3350) and G8 (0.16 M
ammonium sulfate, 0.08 M sodium acetate pH 4.6, 20%
PEG4000, 20% glycerol). Crystals appeared on the second day
and grew to the full size within several days at 20uC.
X-ray data collection and processing
Diffraction data were collected at the Southeast Regional
Collaborative Access Team (SER-CAT) beamline 22-ID at the
Advanced Photon Source, Argonne National Laboratory. Single
crystals were transferred to a cryoprotectant solution (mother
liquor with extra 10–20% glycerol) for approximately 2 min and
then were flash frozen at 100 K in a stream of liquid nitrogen. A
crystal from JCSG-CORE-II condition G8 (named form I)
diffracted X-rays to the resolution of 1.5 A˚. Diffraction data were
indexed, integrated, and scaled with the program XDS [33]. The
crystal belongs to the space group C2 with unit cell parameters
a = 114.9 A˚, b = 46.2 A˚, c = 71.5 A˚, b= 103.4u and contains a
dimer of CrataBL in the asymmetric unit. The estimated
Matthews coefficient is 2.26 A˚3 Da21, corresponding to 45.5%
solvent content. A crystal from JCSG-CORE-II condition D12
(named form II) diffracted X-rays to the resolution of 1.75 A˚.
Diffraction data were also processed with the program XDS. The
crystal also belongs to the space group C2 but with different unit
cell parameters, a = 95.6 A˚, b = 76.3 A˚, c = 62.3 A˚, b= 120.1u,
with a single CrataBL dimer in the asymmetric unit. The
estimated Matthews coefficient is 2.66 A˚3 Da21, corresponding
to 53.9% solvent content. Data processing statistics for both crystal
forms are shown in Table 1.
Structure determination and refinement
The structure of CrataBL was initially determined using
diffraction data of the crystal form I and the resulting coordinates
were subsequently used as the starting model for molecular
replacement with data collected for crystal form II. The structure
of CrataBL was solved by molecular replacement with the
program Phaser [34,35] using the structure of water-soluble
chlorophyll protein (PDB ID: 2DRE) as a starting model. The
latter protein was chosen due to its highest primary structure
identity with CrataBL (.30%). A unique solution representing
two molecules in the asymmetric unit was found for data between
20.0 and 2.5 A˚, with a Log-Likelihood gain of 122.3. The resulting
electron density map was fully interpretable, verifying the
correctness of the solution. Further refinement was performed
with REFMAC5 [36] and PHENIX [34], using all data between
20 and 1.5 A˚, after setting aside 2% of randomly selected
Table 1. Data collection and structure refinement.
Data collection
CrataBL-form I CrataBL-form II
Space group C2 C2
Molecules/a.u. 2 2
Unit cell a, b, c (A˚); 114.9, 46.2, 71.5 95.6, 76.3, 62.3
b (u) 103.4 120.1
Resolution (A˚)* 20.0-1.50 (1.75-1.50) 20.0-1.75 (1.85-1.75)
Rmerge
{ (%) 6.5 (93.2) 5.6 (35.8)
No. of reflections (measured/unique) 427,881/58,600 257,578/38,040
,I/sI. 15.72 (2.43) 20.21 (3.87)
Completeness (%) 99.9 (100.0) 97.0 (96.1)
Redundancy 7.3 (7.3) 6.8 (5.5)
Refinement
Resolution (A˚) 19.95-1.50 19.98-1.75
No. of reflections (refinement/Rfree) 57,427/1,172 37,089/951
R/Rfree
` 0.173/0.208 0.185/0.232
No. atoms
Protein 2572 2576
Ligands 98 154
Water 394 297
R.m.s. deviations from ideality
Bond lengths (A˚) 0.014 0.017
Bond angles (u) 1.8 1.9
PDB ID 4IHZ 4II0
*The highest resolution shell is shown in parentheses.
{Rmerge =ShSi|Ii-ÆIæ|/ShSiIi, where Ii is the observed intensity of the i-th measurement of reflection h, and ÆIæ is the average intensity of that reflection obtained from
multiple observations.
`R=S||Fo|-|Fc||/S|Fo|, where Fo and Fc are the observed and calculated structure factors, respectively, calculated for all data. Rfree was defined in [37].
doi:10.1371/journal.pone.0064426.t001
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reflections (1172 total) for calculation of Rfree [37]. Isotropic
individual temperature factors were refined, with the TLS
parameters added in the final stages of refinement. After several
further rounds of automated refinement and manual correction
using COOT [38], the structural model was finally refined to an
R-factor of 17.3% and Rfree of 20.8%. The structure of crystal
form II was solved with Phaser and the form I coordinates as the
starting model; its refinement was carried out using a protocol
similar to the one reported for crystal form I. The final model was
refined to 1.75 A˚ resolution, resulting in an R-factor of 18.5% and
Rfree of 23.2%. The refinement statistics for the structures of
CrataBL in the two crystal forms are shown in Table 1. The
structures were compared using the Dali server [39] with the set of
Protein Data Bank structures with less than 90% sequence
identity.
Cell viability assay
Cell Lines. The cell lines DU145 (HTB-81TM) and PC3
(CRL-1435TM) were purchased from ATCCH. Cells were
maintained in the Roswell Park Memorial Institute (RPMI) media
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), 100 mg/mL of streptomycin and 100 IU/mL of penicillin,
at 37uC in an atmosphere of 5% CO2. Cell viability was
determined by the modified colorimetric assay utilizing 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
(Sigma Aldrich, St. Louis, USA). DU145 or PC3 were plated in
96-well plates (TPP, Trasadingen, Switzerland) at a density of
5.06103 cells per well for 24 h. Subsequently the cells were treated
with different concentrations of CrataBL (5, 10, 20, and 40 mM) or
soybean trypsin inhibitor (SbTI) (5, 25, 50, 100 mM) prepared in
RPMI media at 37uC in an atmosphere of 5% CO2. After 24, 48,
and 72 h of culture, 10 mL of MTT (5 mg/mL in phosphate
buffered saline, PBS) were added to the wells (2 h, 37uC), followed
by the removal of the medium and addition of 100 mL/well of
dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, USA) to
solubilize the crystals of formazan. The absorbance was measured
Figure 1. Purification of CrataBL. (A) The fraction 30–60% was submitted to ion-exchange chromatography on CM cellulose equilibrated with
10 mM phosphate citrate buffer (PCB), pH 5.5. Two mL fractions were collected at the flow rate 0.3 mL/min. An arrow indicates elution with 10 mM
phosphate citrate buffer, pH 5.5, containing 0.5 M NaCl; (B) Size exclusion chromatography on Superdex 75 equilibrated with 0.15 M NaCl at the flow
rate 0.5 mL/min. (C) The protein fraction was eluted with a linear gradient (5–100%) of 90% acetonitrile in 0.1% TFA in Milli-Q water (solvent B) at the
flow rate of 0.7 mL/min (t= 0.1 min, 5% B; t=5 min, 5% B; t= 30 min, 40% B; t= 50 min, 50% B; t= 60 min, 100% B; t=65–68 min, 0% B).
doi:10.1371/journal.pone.0064426.g001
Table 2. Inhibitory properties of CrataBL.
Enzyme Kiapp
Trypsin 43 mM
Human Factor Xa 8.6 mM
Human neutrophil elastase NI
Human plasma kallikrein NI
Papain NI
Human plasmin NI
Porcine pancreatic kallikrein NI
Bovine chymotrypsin NI
Enzyme inhibition activity was previously described; (NI) no inhibition detected.
doi:10.1371/journal.pone.0064426.t002
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at 540 nm using a spectrophotometer (Packard, SpectraCount).
Each experiment was performed in triplicate.
Cell death analysis by flow cytometry
DU145 and PC3 cells (16105 cells) were seeded on 6-well plates
(TPP, Trasadingen, Switzerland) for 24 h for complete adhesion.
The wells were subsequently washed three times with RPMI
media without FBS (at incubation periods of 15 min at 37uC and
5% CO2). The cells were incubated for 24 h in RPMI media
without FBS to synchronize the cell cycle. Thereafter, the cells
were treated with CrataBL (40 mM) for 24 and 48 h in RPMI
without FBS at 37uC and 5% CO2. At the end of each incubation,
the cells were removed from the plate using trypsin-EDTA
solution (Cultilab, Campinas, Brazil) [40], transferred to cytometry
tubes, washed with 500 mL of binding buffer (BD PharMingen kit),
centrifuged, and resuspended in 50 mL of the same buffer also
containing 3 mL of Annexin V-FITC and 5 mL of propidium
iodide (PI). The reaction mixture was incubated for 30 min in the
dark, and then 300 mL of the same binding buffer was added to
Figure 2. Similarity of CrataBL to others proteins. A comparison of the amino acid sequence of isoform I of CrataBL with the sequences of
structurally similar proteins, as determined with the program Dali [39]. Cysteine residues are shown in black boxes and highly conserved amino acids
are highlighted in gray. Residue positions P1 and P19, between which the proteolytic cleavage occurs, are denoted in box. Asterisks indicate
glycosylation sites in CrataBL. The sequence of isoform II differs in positions 31 (Pro/Leu); 92 (Ser/Leu); 93 (Ile/Thr); 95 (Arg/Gly) and 97 (Leu/Ser).
doi:10.1371/journal.pone.0064426.g002
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each tube and analyzed by flow cytometry (FACSCalibur, BD,
San Diego, USA) [41,42].
Analysis of mitochondrial cytochrome c release
DU145 and PC3 cells were seeded on 13-mm glass coverslips
(56104 cells/well), placed in 24-well plates and incubated for 24 h
at 37uC and 5% CO2 for full adherence. The cells were
subsequently incubated in the RPMI media without FBS for
24 h, followed by the treatment with 40 mM CrataBL in the
RPMI media without FBS, and incubated at 37uC and 5% CO2
for 12 h. At the end of the treatment, the cells were washed with
PBS and the mitochondria were labeled with Mitotracker Deep
Red 633 (1:500) (Molecular Probes) for 20 min in the dark and
fixed with 2% (v/v) paraformaldehyde in PBS for 15 min. The
cells were washed again three times with PBS containing 0.01 M
glycine and then permeabilized with 0.01% saponin for 15 min.
The cells were subsequently stained for 2 h with the primary
antibody, mouse anti-cytochrome c (1:400) (R&D Systems),
followed by staining for 40 min with the secondary antibody,
mouse anti-IgG conjugated with Alexa Fluor 488 (1:500)
(Invitrogen, CA, USA). Cell nuclei were labeled with the
fluorophore DAPI (1:3000) (Invitrogen, CA, USA) for 30 min
and then fixed to slides with 7 mL of fluoromount G (Electron
Microscopy Sciences). Visualization and measurements of the
fluorescence slides were performed in a confocal scanning
microscope Carl Zeiss LSM780 laser model, 636objective, using
oil immersion and a numerical aperture of 1.43. The program
used for image acquisition was Zen 2010.
Caspase 3 activity by flow cytometry
DU145 and PC3 cells (16105 cells) were seeded in each well of
a 6-well plate (TPP, Trasadingen, Switzerland) containing RPMI
media supplemented with 10% FBS for adhesion. The cells were
then washed three times with RPMI media without FBS and
incubated for 24 h. Twenty-four hours later the medium was
replaced with 40 mM of CrataBL and further incubated for 48 h at
37uC and 5% CO2. At the end of the treatment, the cells were
removed from the plate using a trypsin-EDTA solution (Cultilab,
Campinas, Brazil) [40], transferred to cytometry tubes and fixed
with 100 mL of 2% (v/v) paraformaldehyde for 30 min at room
temperature. The cells were resuspended after centrifugation in
200 mL of 0.01% glycine in PBS and incubated for 15 min at
room temperature. The cells were then resuspended again in
200 mL of 0.01% saponin in PBS and incubated for 15 min at
room temperature. Finally, the cells were incubated with 10 mL of
cleaved caspase 3 AlexaFluor 488-conjugated antibody (BD, San
Diego, USA) for 40 min. The results were analyzed by flow
cytometry (FACSCalibur - BD, San Diego, USA).
Statistical analysis
Differences between the mean values were analyzed using a
one-way ANOVA followed by Tukey’s test. Values were
considered to be significant when *p,0.05; **p,0.01;
***p,0.001.
Data deposition
The atomic coordinates and structure factors have been
deposited with the Protein Data Bank, www.rcsb.org (PDB
accession codes 4IHZ and 4II0 for crystal forms I and II,
respectively). The protein sequence data reported here will appear
in the Uniprot Knowledgebase under the accession numbers
B8WI86 and C0HJA4.
Figure 3. Molecular mass of glycosylated CrataBL determined by MALDI-TOF/MS.
doi:10.1371/journal.pone.0064426.g003
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Figure 4. Similarity of CrataBL to protease inhibitors. A comparison of the amino acid sequence of isoform I of CrataBL with the sequences of
BvTI – trypsin inhibitor purified from Bauhinia variegata; BuXI – inhibitor of factor Xa from Bauhinia ungulata; EcTI – trypsin inhibitor purified from
Enterolobium contortisiliquum trypsin inhibitor [42,43]. Cysteine residues are shown in gray and highly conserved amino acids are highlighted in black.
Residue positions P1 and P19, between which the proteolytic cleavage occurs, are denoted in boxes. Asterisks indicate glycosylation sites in CrataBL.
doi:10.1371/journal.pone.0064426.g004
Figure 5. Electron density at the C terminus of molecule A of crystal form I of CrataBL. The 2Fo-Fc map was contoured at 1.2 s level. The
shape of the density corresponding to the C-terminal carboxylate clearly indicates that Gly165, although found in the sequence, is not present in the
isoform forming the crystal. Figure prepared with PyMol [69].
doi:10.1371/journal.pone.0064426.g005
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Results and Discussion
Purification of CrataBL and assessment of its activities
CrataBL is a basic protein (pI.10) that could be purified in a
relatively simple way [17]. The initial steps involved extraction in
0.15 M NaCl and ion exchange chromatography in CM-Cellulose
(Figure 1A). Size exclusion chromatography on a Superdex 75
column (Figure 1B) allowed purification of the protein into a
homogeneous form suitable for structural studies, with only a
single major peak visible after reverse-phase chromatography on a
C18 HPLC column (Figure 1C). Native protein migrates mostly
as a homodimer at the concentration used in the crystallization
trials (see below).
Lectin and hemagglutinating activities of CrataBL were noted
previously [17] and these properties have not been analyzed
further. However, we have assessed the ability of CrataBL to
function as a protease inhibitor. We found that it could inhibit
bovine trypsin and Factor Xa, but no other serine peptidases
including chymotrypsin, plasmin, human neutrophil elastase,
human plasma kallikrein, porcine pancreatic kallikrein, or a
cysteine protease papain (Table 2). Kiapp, calculated using the
equation described by Morrison et al. [32], was 43 mM for trypsin
and 8.6 mM for Factor Xa, indicating that CrataBL is a relatively
weak inhibitor, much less potent than some other inhibitors that
belong to the same family which are often nanomolar of even
picomolar [43,44].
Primary structure, glycosylation, and biochemical
properties of CrataBL
The primary structure of mature CrataBL consists of a single
polypeptide 164 or 165 amino acid long, present in at least two
distinct isoforms, differing in positions 31 (Pro/Leu); 92 (Ser/Leu);
93 (Ile/Thr); 95 (Arg/Gly) and 97 (Leu/Ser) (Figure 2). The C-
terminal Gly165 may be present in only a fraction of the
molecules. The presence of five cysteine residues indicated a
possibility of forming two intramolecular disulfide bonds, the
presence of which was verified by the crystal structures (see below).
Arau´jo et al. [17] estimated the molecular mass of CrataBL at
about 21 KDa on SDS-PAGE and have shown by Schiff staining
that the protein is glycosylated. Further analysis of glycosylation by
mass spectrometry and protein sequence determination has shown
the presence of N-linked oligosaccharides at Asn27 and Asn57.
MALDI-TOF MS analysis of the molecular mass of native protein
gave a peak at m/z 20388, with a shoulder at about 19700
(M+H)+, indicating the presence of an isoform. An additional peak
of 10229 is due to molecular ion (M+2H)+ (Figure 3). The
phenol-sulfuric acid method [27] was used to determine the
concentration of carbohydrate on the protein, indicating ,6%
carbohydrate content.
The molecular mass of carbohydrate moieties were estimated by
the differences between the mass spectrometry of the glycosylated
peptides and their amino acid sequences. In the case of the Asn57,
the molecular weight is shown to be 1,170 Da whereas at Asn27,
additional signals of 162 Da or more were detected (data not
shown).
The sequences of both isoforms of CrataBL show high similarity
to a variety of proteins with b-trefoil fold (Figure 2), including
Kunitz type inhibitors from the STI (soybean trypsin inhibitor)
family [45]. Such inhibitors function by tightly binding to their
target protease and inserting their reactive loop into its active site,
sometimes also acting as slow substrates [2].
The location of the reactive site of CrataBL was determined by
chromatography on trypsin-Sepharose in 0.1 M Tris-HCl,
pH 8.0. After binding to the support, the inhibitor was kept for
30 min on the column and was then eluted with 0.5 M KCl/HCl
pH 2.0 and maintained at this pH. Trypsin bound to Sepharose
hydrolyzes specifically the inhibitor at the reactive site and the
sample was kept in conditions chosen to avoid the re-ligation of the
peptide bond. The resulting modified protein was sequenced and
two N-terminal amino acids were found in the eluate, one of them
corresponding to the N-terminal Ala1 of the intact inhibitor,
whereas the other one could be identified as Ser59. This result
indicates that the latter residue must be present in the P19 position,
as defined by Schechter and Berger [46], thus Ser58 must occupy
the P1 position. The most potent trypsin inhibitors usually contain
a basic residue (Lys or Arg, such as Arg63 in STI [44,45]) in the P1
position. Only a few known Kunitz-P inhibitors have Ser at P1
position [47], but it has been found that the presence of serine in
P19 enhances the interactions with trypsin [48]. The observed site
of cleavage of CrataBL corresponds to the reactive loop in the
majority of known Kunitz-P type inhibitors, such as STI [44]
(Figure 4).
Crystal structure of CrataBL
The three-dimensional structure of CrataBL was determined in
two crystal forms. Both of them were in space group C2 and
contained two molecules in the asymmetric unit, but the unit cell
parameters and crystal packing were different. The structures were
refined at comparatively high resolution, 1.5 A˚ for crystal form I
Figure 6. Overall structure of CrataBL. (A) Stereo view of the three-
dimensional structure of a CrataBL monomer (molecule A of crystal
form I). Three motifs defining the b-trefoil fold are colored in blue,
green, and red. N- and C-termini and the putative reactive loop are
labeled. Two glycosylated residues and attached carbohydrates are
shown in sticks. The carbohydrate attached to the reactive loop is taken
from molecule A in crystal form II. (B) A dimer of CrataBL observed in
both crystal forms, with the two molecules colored red and blue,
respectively. The reactive loops in both monomers are shown in gray.
The secondary structure elements are marked on the molecule shown
on the left. Figure prepared with PyMol [69].
doi:10.1371/journal.pone.0064426.g006
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and 1.75 A˚ for crystal form II, with acceptable geometrical
parameters (Table 1). The final models were complete for all four
independent molecules with residues 1–164 traced. The presence
of very well defined C-terminal carboxylate in molecule A of
crystal form I suggests that the last residue was Ser164 and that
Gly165, although annotated in the primary structure, was not
present in the crystallized protein (Figure 5). Although, as
mentioned above, CrataBL isolated from its natural source is a
mixture of isoforms, it appears that primarily molecules of isoform
I were crystallizing, since the electron density corresponding to
residues that differed between the two isoforms was quite clear.
Extensive glycosylation at Asn27 was noted, with up to four
carbohydrate units attached to that residue being visible. The best
density was present in molecule A of crystal form I, where the
typical plant-type glycosylation pattern [Manb1-4GlcNAcb1-
4(Fuca1-3)GlcNAcb-Asn] [49] could be observed. The carbohy-
drates were less well ordered in other molecules of both crystal
forms. A weak density that could correspond to a carbohydrate
bound to Asn57 in crystal form I did not allow proper modeling.
In crystal form II, however, the density adjacent to Asn57 was
quite clear and allowed modeling of a covalently bound GlcNAc.
Two disulfide bonds were made by Cys33-Cys80 and Cys126-133,
whereas Cys74 was present in all molecules in the form of sulfenic
acid.
The fold of CrataBL consists of a b-trefoil, typical for this
protein family. Such a fold contains twelve b-strands arranged into
three structurally similar units related by pseudo-threefold
symmetry (Figure 6A,B). A search of the unique structures in
the Protein Data Bank with the DALI server [39] identified at least
14 very closely related proteins, with Z-scores in the range 16.7–
19.9 and the reported rmsd of 2.0–2.4 A˚ for between 140 and 151
Ca coordinates. The alignment of the primary structure of
CrataBL with the sequences of these 14 proteins is shown in
Figure 2. Almost none of the individual amino acids are strictly
conserved among all 15 proteins, although pairwise comparisons
of their identity with CrataBL are in the 20–30% range.
Surprisingly, the protein structurally most similar to CrataBL is
the chlorophyll binding protein (PDB ID: 2DRE) which is not a
protease inhibitor at all. A number of other proteins that are very
similar to CrataBL belong to the miraculin subfamily. Although
structural data for miraculin itself are not available, other closely
related proteins, for example a miraculin-like protein from Murraya
koenigii [50], have been studied crystallographically. The clearest
sequence and structural difference between CrataBL and the
proteins listed in Figure 2 is its truncation at the N terminus,
where about a dozen residues present in all other structures of
closely related Kunitz-P inhibitors are not found in CrataBL
(Figure 7A). These residues form a b-hairpin in the other
Figure 7. A comparison of CrataBL with proteins sharing the b-trefoil fold. (A) Superimposed regions of the N termini of CrataBL (green) and
STI (magenta - PDB ID: 1AVW [44]). (B) A dimer of CrataBL (red) compared to the obligatory dimers of CNL (yellow - PDB ID: 3NBD [9]) and GalNAc/Gal-
specific agglutinin from Sclerotinia sclerotiorum (green - PDB ID: 2X2S [50]).
doi:10.1371/journal.pone.0064426.g007
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Figure 8. Effects of CrataBL and SbTI on the viability of the DU145 (A, C) and PC3 (B, D) cell lines, respectively. Cells were incubated in
96-well microplates in the concentration of 56103 cells/100 mL/well. After 24 h, CrataBL, in the final concentrations of 5, 10, 20 and 40 mM, was
incubated at 37uC in an atmosphere of 5% (v/v) CO2 for 24, 48 and 72 h. The viability was determined by MTT colorimetric method. Results represent
the mean 6 standard deviation of three experiments, each conducted in triplicate (*p,0.05; ** p,0.01; *** p,0.001 compared with control cells). In
the absence of CrataBL, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reduction was considered as 100%.
doi:10.1371/journal.pone.0064426.g008
Figure 9. CrataBL induced apoptosis in prostate cancer cells. The cell lines were seeded in 6-well plates for 24 h, followed by washing three
times and incubating with RPMI without FBS for cell cycle synchronization. Afterwards cells were treated with CrataBL (40 mM) or medium (control)
for 24 h (A and B) and 48 h (C and D). The analysis was performed in FACSCalibur flow cytometer using annexin V-FITC and propidium iodide (PI)
staining. The percentage of viable (An2PI2), apoptotic (An+PI2), secondary apoptotic (An+PI+) and necrotic (An2PI+) cells are represented. Data
expressed as mean 6 SD, obtained from experiments performed in triplicate. (*p,0.05; *** p,0.001 compared with control cells).
doi:10.1371/journal.pone.0064426.g009
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structures, but their lack does not seem to affect the stability of the
fold of CrataBL. On the other hand, a shorter N terminus similar
to the one in CrataBL is found in several lectins that exhibit the
same overall fold, for exemple in the Clitocybe nebularis lectin, CNL
[9].
At the concentration of CrataBL used for crystallographic
investigations the protein migrates on a column as a dimer
(Figure 6B), and the asymmetric unit of both crystal forms also
contains a pair of molecules. Taking molecule A in crystal form I
as a reference, the rms deviation between the Ca from those of
molecule B was 0.154 A˚, whereas the rms deviations from crystal
form II coordinates were 0.197 and 0.221 A˚ for molecules A and
B, respectively. The dimers present in both crystal forms are very
similar, with the rms deviation of 0.48 A˚ for all Ca atoms. The two
molecules forming a dimer interact quite extensively with each
other, with the contact area per molecule ,645 A˚2. The putative
reactive loops are not involved in any intermolecular contacts,
either within a dimer or with symmetry-related molecules.
However, it is not clear whether the dimer observed in both
crystal forms of CrataBL is biologically significant. There is no
particular need for dimerization of a protease inhibitor, since
Kunitz-P type inhibitors form 1:1 complexes with their target
enzymes. Dimerization was reported to be important for the
function of some lectins that belong to the b-trefoil family [9,51],
but the interactions responsible for dimerization of these lectins are
very different from those found in the dimer of CrataBL
(Figure 7B).
Since we were not able to obtain crystals of CrataBL with a
target protease such as trypsin, the location of the reactive loop
may only be predicted. However, the observation that CrataBL is
slowly cleaved by trypsin between serines 58 and 59, located on a
loop that is involved in direct interaction with the active site
residues in trypsin and other serine proteases [9], lends credence to
this assumption. It has been previously shown that Kunitz-P
inhibitors are slow substrates and that the cleavage (and re-
ligation) site is always located on the reactive loop. This loop is
most often located between b strands 4 and 5 (although some other
loops may play this role, for example in the potato double-headed
inhibitor [52]). Thus the detailed structural basis of the inhibition
mode by CrataBL still needs to be verified.
The presence of a verified glycosylation site (Asn57 –
Figure 6A) on the putative reactive loop might be one of the
reasons for the low inhibitory activity of CrataBL. However, such
a site is not unique to only this inhibitor. For example, a similarly
located site has been also postulated to be present in the miraculin-
like protein from Murraya koenigii [50], although the published
coordinates do not include a carbohydrate moiety attached to
Figure 10. Scanning confocal microscopy of DU145 (A) and PC3
(B) cells (56104/well). The cells were seeded on 13-mm glass
coverslips, placed in 24-well plates and incubated for 24 h at 37uC, in an
atmosphere of 5% (v/v) CO2. At the end of the incubation period, the
cells were incubated with RPMI without FBS for 24 h. Subsequently the
cells were treated with 40 mM of CrataBL (12 h) in RPMI without FBS at
37uC, in an atmosphere of 5% (v/v) CO2. The cells were washed with PBS
and incubated with Mitotracker Deep Red 633 in the dark. The cell lines
were marked with a primary antibody mouse anti-cytochrome c,
following the incubation with a secondary antibody mouse anti-IgG
conjugated with Alexa Fluor 488 (green). The nuclei were marked with
DAPI (blue) and the coverslips fixed to slides with fluoromount G. The
images were acquired using the confocal scanning microscope Carl
Zeiss LSM780. Bar = 10 mm.
doi:10.1371/journal.pone.0064426.g010
Figure 11. Analysis of caspase-3 activation in prostate cancer cell lines. DU145 (A) and PC3 (B) (16105 cells) cell lines were seeded in 6-well
plates, following the same protocol for apoptosis with annexin V/FITC and PI staining. Cells treated with CrataBL (40 mM), containing RPMI without
FBS were incubated for 48 h at 37uC and 5% (v/v) CO2. The cells were incubated with 10 mL of cleaved caspase 3 Alexa Fluor 488-conjugated antibody
for 40 min and analyzed in FACSCalibur flow cytometer. As control, the cells were treated with medium only. The area in black represents the control
and in white, cells treated with CrataBL.
doi:10.1371/journal.pone.0064426.g011
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Asn64 (the presence of extra density next to that residue is,
however, noted). Similarly to CrataBL, the miraculin-like protein
is also a comparatively weak trypsin inhibitor.
Cell viability
The viability of the DU145 and PC3 cells lines after incubation
with CrataBL for 24, 48, and 72 h was investigated by
colorimetric MTT assay. Several recent studies have used the
MTT assay to determine cell proliferation [53,54,55]. The method
consists in reducing the tetrazolium salt (MTT) to formazan. As
shown in Figure 8 (A–B), CrataBL inhibits the viability of the
prostate cancer cell lines DU145 and PC3 in contrast to SbTI that
did not interfere on DU145 and PC3 cell viability for 24 h
(Figure 8 C) and poorly on PC3 for 48 h (Figure 8 D). In the
period of 24 h, the cell viability was inhibited in a dose-dependent
manner, in response to increasing concentrations of CrataBL (5–
40 mM). CrataBL, applied in the concentration of 40 mM for 48 h,
inhibited 52.7% and 56.9% of the viability of DU145 and PC3,
respectively. In the period of 72 h, the percentage of inhibition of
cell viability is lowered. Lectins have been known to bind to cancer
cell membranes or receptors causing cytotoxicity, apoptosis, and
inhibition of tumor growth [56]. Thus, these results are
particularly interesting since they suggest that it might be
worthwhile to investigate the effect of CrataBL on prostate cancer
cell lines as a possible biotechnological tool. The reduction of
MTT is generally attributed to mitochondrial activity, but it has
also been related by non-mitochondrial enzymes of the endosomes
and lysosomes [57].
Cell death induced by CrataBL in DU145 and PC3 cell
lines
To quantify the manner of cell death, 40 mM of CrataBL was
applied to DU145 and PC3 cells for 24 and 48 h, using annexin
V/FITC and PI staining. As shown in Figure 9, both cell lines
exhibit significant death due to apoptosis (p,0.001). DU145
treated with CrataBL increased the number of apoptotic cells to
57.1% of the total cell population after 48 h. PC3 cells increased
the amount of apoptosis observed in the presence of CrataBL to
80.7%, whereas the apoptotic index for the PC3 control cells was
only 8.2%. As apoptosis is also characterized by the loss of
mitochondrial function [58] and one of the mechanisms of cell
death by apoptosis is the release of cytochrome c by mitochondria
[59], an assay to verify such release was carried out (Figure 10).
CrataBL induces the release of cytochrome c in both cell lines,
confirming the induction of cell death in these lines via
mitochondria. Apoptosis via mitochondria, also called an intrinsic
pathway, is regulated by proteins from the Bcl-2 family which
control the permeability of the mitochondrial membrane [60].
The enzymes that are central component of the apoptotic
machinery are caspases, cysteine-dependent, aspartate-directed
proteases [61]. These enzymes cleave important intracellular
proteins associated with apoptosis [62]. CrataBL activates caspase-
3 in DU145 and PC3 cells (Figure 11), similarly to what Jow et al.
[63] found on leukemia cells treated with beauvericin, a cyclic
hexadepsipeptide. Zhang et al. [64] showed that CrataBL strongly
binds a number of sulfated carbohydrates whereas binding of other
carbohydrates is insignificant, concluding that charge-charge
interactions are responsible for lectin properties of this protein.
In Figure 12 we show the positively charged surface regions in
CrataBL, confirming their basic character. On the basis of these
findings we may suggest that CrataBL binds to the surface of the
target cells through binding of sulfated glycosaminoglycans, such
as chondroitin sulfate and dermatan sulfate. The presence of
increased amounts of these carbohydrates in prostate cancer cells
has been shown before [65]. Glycosaminoglycans are able to
potentiate proteases activities, mainly cathepsins [66,67] and
kallikrein [68]. Thus CrataBL attached to sulfated glycosamino-
glycans may interfere with the activities of extracellular proteases,
either by directly inhibiting their activity or, indirectly, by
shielding the enzymes from the cell surface-bound glycosamino-
glycans, impairing the potential of these compounds to potentiate
the activity of proteases.
Conclusions
To conclude, the sequence and three-dimensional structure of
CrataBL show extensive similarity to protease inhibitors of the
Kunitz-type, although the inhibitory activity is weak (in the
micromolar range). Our results suggested that CrataBL activated
the intrinsic pathway by caspase-3 activation through of the
release of cytochrome c by the mitochondria. The precise
mechanism of CrataBL action needs to be clarified, but due to
its properties it is possible to postulate that as a lectin it may block
the binding of glycoproteins on tumor cell surface, whereas in its
inhibitory capacity it may reduce trypsin-like proteolytic activity,
thus preventing the processes of malignant invasion and the
altered growth control of tumor cells. The importance of the latter
activity may be less than of the former one, due to comparatively
weak inhibitory activity of CrataBL. However, further investiga-
tions are required in order to evaluate the effect of this protein in
vivo and the structural basis of its activity.
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